Oppenheimer Initiates Coverage On OnKure Therapeutics with Outperform Rating, Announces Price Target of $35
Portfolio Pulse from Benzinga Newsdesk
Oppenheimer has initiated coverage on OnKure Therapeutics with an Outperform rating and set a price target of $35.
October 10, 2024 | 12:07 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Oppenheimer has initiated coverage on OnKure Therapeutics with an Outperform rating and a price target of $35, indicating a positive outlook.
The initiation of coverage with an Outperform rating and a specific price target of $35 by a reputable analyst can positively influence investor sentiment and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100